Solifenacin: Pharmacology and clinical efficacy

Expert Review of Clinical Pharmacology

Volumn 2, Issue 3, 2009, Pages 239-253

  Robinson, Dudley ^a   Cardozo, Linda ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antimuscarinics; Detrusor overactivity; Overactive bladder; Solifenacin; Urinary incontinence

Indexed keywords

KETOCONAZOLE; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE;

ANTICHOLINERGIC SYNDROME; ANTIMUSCARINIC ACTIVITY; AREA UNDER THE CURVE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; MUSCLE RELAXATION; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PREVALENCE; QT INTERVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; XEROSTOMIA;

EID: 70149095259     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.3     Document Type: Review

References (75)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society. Neurourol. Urodyn. 21, 167-178 (2002).
2. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. 104, 1374-1379 (1997).
3. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficency of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. 104, 988-993 (1997).
4. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared to placebo in the treatment of overactive bladder: systematic review. BMJ 326(7394), 841-844. (2003).
5. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 4, CD003781 (2006).
6. Stewart WF, Corey R, Herzog AR et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int. Urogynaecol. J. 12(3), S66 (2001).
7. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87(9), 760-766 (2001).
8. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study. Eur. Urol. 50, 1306-1315 (2006).
9. Andersson K-E. The overactive bladder: pharmacologic basis of drug treatment. Urology 50(6A Suppl.), 74-84 (1997).
10. Hashim H, Abrams P. Do symptoms of overactive bladder predict urodynamic detrusor overactivity? Neurourol. Urodyn. 23, 484 (2004).
11. Caulfield MP, Birdsall NJ. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50, 279 (1998).
12. Yamaguchi O, Shisida K, Tamura K et al. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J. Urol. 156, 1208 (1996).
13. Harris DR, Marsh KA, Birmingham AT et al. Expression of muscarinic M3 receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J. Urol. 154, 1241 (1995).
14. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148, 565-578 (2006).
15. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 64, 419 (1999).
16. Braverman AS, Ruggieri MR. The M2 receptor contributes to contraction of the denervated rat urinary bladder. Am. J. Physiol. 275, 1654 (1998).
17. 2+ mobilization study in monkey cells. Life Sci. 74, 843-853 (2004).
18. Ikeda K. Affinity of YM905 for human muscarinic M1, M2 and M3 receptors. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D199803214-02.00. International Study ID: 905-PH-002 (1998).
19. Suzuki M. Inhibitory effect of YM905 on carbachol-induced contraction of guinea pig urinary bladder. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9803231-1. International Study ID: 905-PH-007 (1998).
20. Ikeda K, Kobayashi S. Effects of YM905, oxybutynin and darifenacin on carbachol induced intracellular calcium mobilization by dispersed longitudinal smooth muscle cells of guinea pig colon. Yamanouchi Pharmaceutical Co. Ltd. Registration No. D199803320-02.00. International Study ID: 905-PH-006 (1998).
21. 2+ mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D199803217-02.000. International Study ID: 905-PH-005 (1998).
22. Okutsu H, Noguchi Y, Ohtake A, Suzuki M, Sato S, Sasamata M. Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Biol. Pharm. Bull. 30, 2324-2327 (2007).
23. Saitoh C, Iizumi Y. Effect of YM-67905 on mictuition reflex in anesthetised rats. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9802853-1. International Study ID: 905-PH-011 (1998).
24. Ikeda K. Effect of chronic doses of YM905 on carbachol induced salivary secretion in mice. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D199803318-02.00. International Study ID: 905-PH-020 (1998).
25. Ohtake A, Ukai M, Hatanaka T et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. 492, 243-250 (2004).
26. Katz IR, Sands LP, Bilker W, Difilippo S, Boyce A, D'Angelo K. Identification of medication that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. 46, 8-13 (1998).
27. Yanagihara T. Plasma concentrations of the unchanged drug after repeated oral administration of YM905 to dogs. Yamanouchi Pharmaceutical Co. Ltd Registration No: D9803132-1. International Study ID: 905-ME-004 (1998).
28. Yanagihara T. Plasma concentrations of the unchanged drug and its metabolite BY-348C after single intravenous and oral administration of YM905 to rats. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9802939-1. International Study ID: 905-ME-002 (1998).
29. Ucida T, Krauwinkel WJ, Mulder H, Smulders RA. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomised crossover trial. Br. J. Clin. Pharmacol. 58, 4-7 (2004).
30. Yanagihara T. Plasma concentrations of the unchanged drug after single intravenous and oral administration of YM905 in dogs. Yamanouchi Pharmaceutical Co. Ltd. Registration No: D9802940-1. International Study ID: 905-ME-003 (1998).
31. Yanagihara T. In vitro plasma protein binding of YM905. Yamanouchi Pharmaceutical Co Ltd. Registration No.: D199803314-02.00. International study ID: 905-ME-007 (1998).
32. Kuipers ME, Krauwinkel WJ, Mulder H, Visser N. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs RD 5, 73-81 (2004).
33. Yanagihara T. Comparison of in vitro metabolic patterns of YM905 among various species. Yamanouchi Pharmaceutical Co Ltd. Registration No: D9803351-1. International study ID: 905-ME-009 (1998).
34. Onderwater RCA. Identification of human liver CYP isoforms involved in the metabolism of YM905. Yamanouchi Europe BV. Registration No: D199900072-01.00. International Study ID: 905-ME-020 (1999).
35. Nakamura E. Absorption, distribution, metabolism and excretion of radioactivity after oral administration of 14C-YM905 to rats. Yamanouchi Pharmaceutical Co Ltd. Registration No: D9802237-1 International Study ID: 905-ME-001 (1997).
36. Smith N, Grimes I, Ridge S, Tempel D, Uchida T. YM905 is effective and safe as treatment of overactive bladder in women and men. Neurourol. Urodyn. 21(4), 138-139 (2002).
37. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine controlled Phase II dose finding study. BJU Int. 93, 71-77 (2004).
38. Chapple CR, Arano P, Bosch JLHR, De Ridder D, Kramer AEJL, Ridder AM. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled Phase II dose finding study. Poster 75. 32nd Annual. Meeting of the International Continence Society. Heidelberg, Germany, 28-30 August 2002.
39. Chapple CR, Arano P, Bosch JLHR, De Ridder D. Kramer AEJL, Ridder AM. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled Phase II dose finding study. Neurourol. Urodyn. 21(4), 381-382 (2002).
40. Gittelman MC. The efficacy and safety of solifenacin in adults with overactive bladder; a multicentre, placebo controlled study. Int. J. Gynaecol. Obstet. 83, 94 (2003).
41. Cardozo L, Lisec M, Millard R et al. Randomised double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. 172, 1919-1924 (2004).
42. Chapple CR, Rechberger T, Al-Shukri S et al. YM-905 Study Group. Randomised double blind placebo and tolterodine controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 93, 599-604 (2004).
43. Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. 7(3), 376-384 (2005).
44. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol. 48, 483-487 (2005).
45. Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder related incontinence from pooled analysis of Phase III trials evaluating treatment with solifenacin. Int. Urogynaecol. J. 17, 512-519 (2006).
46. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr. Med. Res. Opin. 22, 41-48 (2006).
47. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am. J. Geriatr. Pharmacother. 4, 14-24 (2006).
48. Chapple CR, Martinez-Garcia R, Selvaggi L; STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. 48, 464-470 (2005).
49. Chapple CR, Fianu-Jonsson A, Indig M et al.; STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4mg. Eur. Urol. 52, 1195-1203 (2007).
50. Chancellor MB, Zinner N, Whitmore K et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12 week, multicentre, open label, flexible dose study. Clin. Ther. 30, 1766-1781 (2008).
51. Yamaguchi O, Marui E, Kakizaki H et al.; Japanese Solifenacin Study Group. Randomised, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 100, 579-587 (2007).
52. Wesnes K, Edgar C, Tretter R, Patel H, Bolodeoku J. Solifenacin is not associated with cognitive impairment or sedation in the elderly; the randomised double-blind SCOPE study. Poster presentation. 38th Annual Meeting of the International Continence Society, Cairo, Egypt, 2008.
53. Mattiasson A, Morton R, Bolodeoku J. Solifenacin alone and with simplified bladder retraining in overactive bladder syndrome: the prospective randomised SOLAR study. Poster Presentation. 38th Annual Meeting of the International Continence Society, Cairo, Egypt, 20-24 October 2008.
54. Garley AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare Open Label Trial. Clin. Ther. 28, 1935-1946 (2006).
55. Lucente V, Ostergard D, Davila GW, Forero-Schwanhaeuser S. Patient reported outcomes in 3 cohorts of patients defined by length of time as acute or chronic overactive bladder: an analysis of more than 2200 patients in the Vesicare open label trial (VOLT). 37th Annual Meeting of the International Continence Society. Rotterdam, The Netherlands, August (2007).
56. Capo JP, Lucente V, Forero-Schwanhaeuser S. Solifenacin use in elderly patients with overactive bladder: VOLT and VERSUS data. Poster Presentation. 38th Annual Meeting of the International Continence Society, Cairo, Egypt, October (2008).
57. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder syndrome: current concepts and future prospects. BJU Int. 95, 335-340 (2005).
58. Cardozo L, Hebdorfer E, Milani R et al.; for the SUNRISE study group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder; results from a randomised, double-blind, placebo-controlled, rising dose trial. BJU Int. 102, 1120-1127 (2008).
59. Karram MM, Toglia MR, Serels SR et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder; results from VENUS, a randomised double blind placebo controlled trial. Urology 73, 14-18 (2009).
60. Cardozo L, Dixon A. Increased warning time with Darifenacin: a new concept in the management of urinary urgency. J. Urol. 173, 1214-1218 (2005).
61. Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the pharmacokinetics of solifenacin in men and women. Int. J. Clin. Pharmacol. Ther. 43, 227-238 (2005).
62. Fuder H. A double blind, randomised, placebo controlled rising study in elderly male and female volunteers to evaluate safety, tolerability and pharmacokinetics of multiple dosing with YM905. Yamanouchi Europe BV. Registration No: D9803294-1. International Study ID: 905-CL-004.
63. Van Aplen W. A placebo controlled dose rising study in healthy male volunteers to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of single oral dosages of YM905. Clinical Pharmacology Research Department, Yamanouchi Europe BV. Registration No: D200001570-01.00. International Study ID: 905-CL-001 (1998).
64. Swart PJ, Krauwinkel WJ, Smulders RA, Smith NN. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 99, 33-36 (2006).
65. Taekema-Roelvink ME, Swart PJ, Kuipers ME, Krauwinkel WJ, Visser N, Smulders RA. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double blind, placebo controlled study. Clin. Ther. 27, 1403-1410 (2005).
66. Smulders RA, Kuipers ME, Krauwinkel WJJ. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Br. J. Clin. Pharmacol. 62, 210-217 (2006).
67. Smulders RA, Smith NN, Krauwinkel WJ, Hoon TJ. Pharmacokinetics, safety and tolerability of solifenacin in patients with renal insufficiency. J. Pharmacol. Sci. 103, 67-74 (2007).
68. Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J. Pharmacol. Sci. 102, 405-412 (2006).
69. Michel MC, Wetterauer U, Vogel M, de al Rossette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12 week open label post-marketing surveillance study. Drug Saf. 31, 505-514 (2008).
70. Hoebeke P, Decaestecker K, Raes A, Dehoorne J, Vande Walle J, Van Laecke E. Safety and efficacy of solifenacin in the treatment of therapy sesistant overactive bladder of childhood. XVII Annual Congress of the European Society Paediatric Urology. Athens, Greece, 27-29 April 2006.
71. Kroll P, Jankowski A, Mankowski P et al. Application of solifenacin in children with neurogenic bladder below six years of age. BJU Int. 100(S3), 30 (2007) (Abstract PP41).
72. Hakkaart L, Verboom P, Phillips R, Al MJ. The cost utility of solifenacin in the treatment of overactive bladder. Int. Urol. Nephrol. DOI: 10.1007/s11255-008-9448-2 (2008).
73. Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost - utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr. Med. Res. Opin. 24(8), 2173-2179 (2008).
74. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladden an update of a systematic review. Eur. Urol. 54, 543-562 (2008).
75. Novara G, Galfano A, Secco S et al. A systematic review and meta-analysis of randomised controlled trials with antimuscarinic drugs for overactive bladder. Eur. Urol. 54, 740-763 (2008).